Kymera Therapeutics (KYMR) Operating Leases: 2019-2025
Historic Operating Leases for Kymera Therapeutics (KYMR) over the last 5 years, with Sep 2025 value amounting to $68.5 million.
- Kymera Therapeutics' Operating Leases fell 7.04% to $68.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $68.5 million, marking a year-over-year decrease of 7.04%. This contributed to the annual value of $72.4 million for FY2024, which is 5.98% down from last year.
- Kymera Therapeutics' Operating Leases amounted to $68.5 million in Q3 2025, which was down 1.98% from $69.8 million recorded in Q2 2025.
- Kymera Therapeutics' Operating Leases' 5-year high stood at $77.0 million during Q4 2023, with a 5-year trough of $12.1 million in Q4 2022.
- In the last 3 years, Kymera Therapeutics' Operating Leases had a median value of $72.4 million in 2024 and averaged $72.2 million.
- As far as peak fluctuations go, Kymera Therapeutics' Operating Leases fell by 8.15% in 2022, and later soared by 534.18% in 2023.
- Kymera Therapeutics' Operating Leases (Quarterly) stood at $13.2 million in 2021, then decreased by 8.15% to $12.1 million in 2022, then soared by 534.18% to $77.0 million in 2023, then decreased by 5.98% to $72.4 million in 2024, then dropped by 7.04% to $68.5 million in 2025.
- Its Operating Leases was $68.5 million in Q3 2025, compared to $69.8 million in Q2 2025 and $71.2 million in Q1 2025.